Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P51114

UPID:
FXR1_HUMAN

ALTERNATIVE NAMES:
FMR1 autosomal homolog 1; hFXR1p

ALTERNATIVE UPACC:
P51114; A8K9B8; Q7Z450; Q8N6R8

BACKGROUND:
The RNA-binding protein FXR1, with aliases FMR1 autosomal homolog 1 and hFXR1p, is a regulator of mRNA translation and stability, crucial for muscle development, neurogenesis, and spermatogenesis. It binds to AU-rich elements in mRNAs, promoting the formation of cytoplasmic ribonucleoprotein granules that concentrate mRNAs with regulatory factors, thereby influencing the translation of key proteins such as MYC and CDKN1A.

THERAPEUTIC SIGNIFICANCE:
Given FXR1's critical role in congenital myopathies 9A and 9B, diseases marked by muscle weakness and developmental challenges, targeting this protein could offer new avenues for treatment. The exploration of RNA-binding protein FXR1's function presents a promising pathway for developing therapies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.